United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

profile pharma ltd - safinamide methansulfonate - tablet - 100mg

Israel - English - Ministry of Health

medison pharma ltd - safinamide as methanesulfonate - film coated tablets - safinamide as methanesulfonate 100 mg - safinamide - xadago is indicated for the treatment of adult patients with idiopathic parkinson’s disease (pd) as add-on therapy to a stable dose of levodopa (l-dopa) alone or in combination with other pd medicinal products in mid-to late-stage fluctuating patients.

Israel - English - Ministry of Health

medison pharma ltd - safinamide as methanesulfonate - film coated tablets - safinamide as methanesulfonate 50 mg - safinamide - xadago is indicated for the treatment of adult patients with idiopathic parkinson’s disease (pd) as add-on therapy to a stable dose of levodopa (l-dopa) alone or in combination with other pd medicinal products in mid-to late-stage fluctuating patients.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

profile pharma ltd - safinamide methansulfonate - tablet - 50mg

Canada - English - Health Canada

valeo pharma inc - safinamide (safinamide mesylate) - tablet - 50mg - safinamide (safinamide mesylate) 50mg - monoamine oxidase b inhibitors

Canada - English - Health Canada

valeo pharma inc - safinamide (safinamide mesylate) - tablet - 100mg - safinamide (safinamide mesylate) 100mg - monoamine oxidase b inhibitors

Singapore - English - HSA (Health Sciences Authority)

eisai (singapore) pte. ltd. - safinamide mesylate eqv safinamide - tablet, film coated - safinamide mesylate eqv safinamide 50mg

European Union - English - EMA (European Medicines Agency)

zambon spa - safinamide methanesulfonate - parkinson disease - anti-parkinson drugs - xadago is indicated for the treatment of adult patients with idiopathic parkinson’s disease (pd) as add-on therapy to a stable dose of levodopa (l-dopa) alone or in combination with other pd medicinal products in mid-to late-stage fluctuating patients.